Why 2019 is shaping up to be an important year for Zimmer Biomet — 5 things to know

Written by Angie Stewart | September 03, 2019 | Print  |

This is an important year for Zimmer Biomet's pipeline and commercial strategy, according to Zacks Equity Research.

Five insights:

1. Zimmer Biomet's shares grew 10.2 percent in the past six months, outperforming the 8.4 percent industry decline.

2. Zimmer Biomet reported slow top-line growth in the second quarter of 2019 but still beat expectations. The musculoskeletal healthcare company had strong performance in the Asia Pacific, Europe, Middle East and Africa regions, and its knee business gained traction in the Americas.

3. However, pricing pressure in the Americas and Europe has been a persistent concern for Zimmer Biomet, offsetting its top-line growth. The company's adjusted operating margin was hurt by rising costs and expenses.

4. In recent months, Zimmer Biomet has had success with product launches. The company secured a number of regulatory clearances for the ROSA platform's knee, brain and spine applications. It also launched its my mobility digital health platform and the Persona Partial and Cementless partial knee implant.

5. Quality remediation and supply recovery efforts are also priorities for the company. Zimmer Biomet is on track to complete its remediation plan on the Warsaw North campus by the end of the year.

More articles on devices: 
NASS unveils '20 Under 40' spine surgeons for 2019
Dr. Death to hit TV screens: A timeline of the former neurosurgeon's case
How spine, neurosurgery departments are evolving — key thoughts from 4 leaders 

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months